1. Acknowledgement to Referees

   Acknowledgement to Referees 28 October 2021 Pages: 741 - 745

2. Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments

   • Christine Blome
   • Matthias Augustin
   • Toni Maria Klein

   Current Opinion Open access 12 August 2021 Pages: 747 - 755

   

3. Psychosocial Effects of Vitiligo: A Systematic Literature Review

   • Khaled Ezzedine
   • Viktoria Eleftheriadou
   • Amit G. Pandya

   Systematic Review Open access 23 September 2021 Pages: 757 - 774

   

4. Appraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons

   • Anne Sofie Frølunde
   • Jacob Pontoppidan Thyssen
   • Christian Vestergaard

   Review Article 28 July 2021 Pages: 775 - 783

   

5. The Use of Lasers and Light Devices in Acne Management: An Update

   • Monica K. Li
   • Chaocheng Liu
   • Jeffrey T. S. Hsu

   Review Article 21 July 2021 Pages: 785 - 800

   

6. Investigational Treatments for Epidermolysis Bullosa

   • Ping-Chen Hou
   • Han-Tang Wang
   • Chao-Kai Hsu

   Review Article 22 July 2021 Pages: 801 - 817

   

7. Sunscreens and Photoaging: A Review of Current Literature

   • Linna L. Guan
   • Henry W. Lim
   • Tasneem F. Mohammad

   Review Article 13 August 2021 Pages: 819 - 828

8. The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation

   • Nada Elbuluk
   • Pearl Grimes
   • Sewon Kang

   Review Article 01 September 2021 Pages: 829 - 836

   

9. Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions

   • Marissa Contento
   • Abigail Cline
   • Marian Russo

   Review Article 21 July 2021 Pages: 837 - 851

   

10. Ceramides in Skin Health and Disease: An Update

    • Yoshikazu Uchida
    • Kyungho Park

    Review Article 20 July 2021 Pages: 853 - 866

    

11. Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts

    • Scott Guenthner
    • Wendy McFalda
    • Melissa Olivadoti

    Original Research Article Open access 13 September 2021 Pages: 867 - 875

    

12. Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial

    • Yan Zhao
    • Litao Zhang
    • Jianzhong Zhang

    Original Research Article 09 August 2021 Pages: 877 - 889

    

13. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020

    • Patrick M. Jedlowski
    • Mahdieh F. Jedlowski
    • Maryam T. Fazel

    Original Research Article 21 July 2021 Pages: 891 - 900

    

14. Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study

    • Emma Borg
    • Henrik Thoning

    Letter to the Editor Open access 27 October 2021 Pages: 901 - 902

15. Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study”

    • Tiago Torres
    • Andrea Chiricozzi
    • Luis Puig

    Letter to the Editor 27 October 2021 Pages: 903 - 904

16. Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

    • Eric L. Simpson
    • Jonathan I. Silverberg
    • Susan Johnson

    Correction 13 October 2021 Pages: 905 - 905